Skip to Content

Dupixent Approval History

FDA Approved: Yes (First approved March 28, 2017)
Brand name: Dupixent
Generic name: dupilumab
Dosage form: Injection
Company: Sanofi and Regeneron Pharmaceuticals, Inc.
Treatment for: Atopic Dermatitis, Asthma

Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.

Development History and FDA Approval Process for Dupixent

DateArticle
Jun 26, 2019Approval FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
Mar 11, 2019Approval FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
Oct 19, 2018Approval FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
Mar 28, 2017Approval FDA Approves Dupixent (dupilumab) for Eczema
Mar  4, 2017Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent (dupilumab) in Moderate-to-Severe Atopic Dermatitis
Oct  1, 2016Sanofi and Regeneron Announce Positive Dupixent (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine
Sep 26, 2016Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Jun  6, 2016Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Apr  1, 2016Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Two Phase 3 Trials in Inadequately Controlled Moderate-To-Severe Atopic Dermatitis Patients
Feb  2, 2016Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data
May 18, 2015Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma
Nov 20, 2014Sanofi And Regeneron Announce That Dupilumab Has Received FDA Breakthrough Therapy Designation In Atopic Dermatitis
Nov 11, 2014Sanofi And Regeneron Announce Positive Results From Phase 2b Study of Dupilumab
Oct 20, 2014Sanofi And Regeneron Announce Start Of Phase 3 Study Of Dupilumab in Patients With Atopic Dermatitis
Sep 30, 2014Sanofi and Regeneron Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
Jul  9, 2014Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab for Atopic Dermatitis
May 21, 2013Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma
Mar  4, 2013Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide